(Q30407650)

21 June 2017

1 reference

title

Prospects for controlling future pandemics of influenza (English)

1 reference

21 June 2017

0 references

1 reference

James S Robertson

1

1 reference

21 June 2017

Stephen C Inglis

series ordinal

2

1 reference

21 June 2017

publication date

22 September 2011

1 reference

21 June 2017

1 reference

21 June 2017

volume

162

1 reference

21 June 2017

issue

1-2

1 reference

21 June 2017

page(s)

39-46

1 reference

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Live attenuated vaccines for pandemic influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Using plant cells as influenza vaccine substrates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

FluBlok, a next generation influenza vaccine manufactured in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Research and development of universal influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

A highly conserved neutralizing epitope on group 2 influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Strategies for containing an emerging influenza pandemic in Southeast Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

M2e-based universal influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

The annual production cycle for influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Influenza virus-like particles as pandemic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

The development of live attenuated cold-adapted influenza virus vaccine for humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Neuraminidase inhibitors: zanamivir and oseltamivir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

The first influenza pandemic of the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

The virulence of pandemic influenza A (H1N1) 2009: an epidemiological perspective on the case-fatality ratio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Quantifying selection and diversity in viruses by entropy methods, with application to the haemagglutinin of H3N2 influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Developing vaccines to combat pandemic influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

The development of vaccine viruses against pandemic A(H1N1) influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

The pathogenic determinant of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Swine flu agitates the adjuvant debate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

1918 Influenza: the mother of all pandemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

Avian influenza virus infections in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.09.024

10.1016/J.VIRUSRES.2011.09.024

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference